Drug intelligence / Profile preview

BR-CM01

Development stage: Preclinical
Lead developer: BlueRock Therapeutics
Modality: iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
Administration: Intramyocardial

Overview

BR-CM01 is an investigational cell therapy being developed by BlueRock Therapeutics for the treatment of heart failure. It is designed to replace damaged cardiomyocytes (heart muscle cells) in heart tissue with new, healthy cells derived from pluripotent stem cells, with the goal of restoring cardiac function and improving patient outcomes. The therapy is currently in preclinical development and represents a regenerative medicine approach targeting cardiovascular disease[1][2][4].

Beyond the preview

Go deeper on BR-CM01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BR-CM01.

Explore the full profile